未来专利过期的药品清单
Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Estimated Dates of Possible First Time Generic/ Rx-to-OTC Market Entry
2009 US Retail Sales:
(in millions)^
Year
2010 2010 2011 2011 2011 2011 2011 2011
Period
4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Mar) 2Q (Apr) 2Q (Apr) 2Q (Apr) 2Q (Apr) 2Q (Jun) 2Q (Jun) 3Q (Jul) 4Q (Oct) 4Q (Nov) 4Q (Nov) 4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Jan)
Brand Name
Aricept® Quixin® Rythmol® SR Xalatan Accolate® Aromasin® Femara® Lotrel®
Generic name
levofloxacin ophthalmic solution propafenone extended-release
capsule
$2 $106
amlodipine/benazepril
(approved and briefly launched 5/07)
$360
2011 2011 2011 2011 2011 2011 2011 2011 2012 2012
Nasacort AQ® Levaquin® Uroxatral®
Zyprexaand Zyprexa
Zydis
Solodyn® Caduet® Lipitor® Tazorac® Anzemet®
Clarinex & Clarinex-D(planning OTC prior to
1
generic availability)
triamcinolone nasal
spray
(previously approved, not
launched 7/09)
$272
alfuzosin extended-release tablet
olanzapine minocycline extended-release tablet
(previously approved, briefly launched)
$196 Zyprexa: $1,968 Zydis: $156
$588 $362
amlodipine/ atorvastatin
desloratadine and desloratadine/ pseudoephedrine
Clarinex: $217 Clarinex D: $39
Information current as of August 2010. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
热门文档